GKOS Latest Press Releases

-- October 9, 2026 --

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose TR in Combination with Cataract Surgery Business Wire 7:00 AM

-- October 8, 2026 --

Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases Business Wire 7:00 AM

-- October 7, 2026 --

Glaukos Announces Positive Three-Year Epioxa Results Demonstrating Durable Clinical Outcomes in Keratoconus Business Wire 4:05 PM

Glaukos to Release Third Quarter 2026 Financial Results after Market Close on October 28 Business Wire 7:00 AM

-- September 23, 2026 --

Glaukos Partners with NBA Champion Stephen Curry to Launch 'Could it be KC?' Campaign to Raise Awareness of Keratoconus Business Wire 7:00 AM

-- August 19, 2026 --

Glaukos Announces Participation in Wells Fargo Healthcare Conference Business Wire 7:00 AM

-- July 29, 2026 --

Glaukos Announces Second Quarter 2026 Financial Results Business Wire 4:05 PM

-- July 27, 2026 --

Glaukos Announces Completion of Patient Enrollment in 510(k) Pivotal Study for PRESERFLO MicroShunt Business Wire 7:00 AM

-- July 8, 2026 --

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29 Business Wire 7:00 AM

-- June 25, 2026 --

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis Business Wire 7:00 AM

Market Data Delayed 15 Minutes